Efficacy and safety of leflunomide for IgA nephropathy：A meta-analysis

Abstract

Abstract:

AIM: To evaluate efficacy and safety of leflunomide for the treatment of IgA nephropathy (IgAN). METHODS: Databases including PubMed, MEDLINE, The Cochrane Library, Clinical trails and CBM, CNKI, VIP, WanFang Data were searched before May 2016, the domestic conference data and relevant published articles were also searched manually. All the RCTs were assessed according to risk bias tools. Software Revman5.3 was used to conduct analysis. RESULTS:A total of 11 RCTs involving 589 patients with IgAN were included. The results of meta-analyses showed that: There were significant advantages between LEF+Ped and single Ped group in the complete remission rate (RR=1.40，95%CI：1.02-1.93，P=0.04), the overall effective rate (RR=1.18，95%CI：1.06-1.32，P=0.004). The overall incidence rate of adverse reaction showed no difference. LEF+Ped group and CTX/MMF+Ped showed similar effectiveness, but incidence rate of adverse reaction (RR=0.21，95%CI：0.11-0.39，P＜0.000 01）in LEF+Ped group was less than CTX+Ped group. LEF+ACEI group and ACEI showed similar effectiveness and safety, but leflunomide could lower UTP and increase Alb. CONCLUSION: LEF has a similar effectiveness compared with CTX and MMF in treatment of IgAN, but it presents better effect and safty than Ped, which is referential for clinical application.

Key words: leflunomide, IgA nephropathy, meta-analysis, randomized controlled trials

CLC Number:

R692

HANG Yongfu, LU Guoyuan, SHEN Lei, GAO Jie, QIAO Qing, LI Ming, SHA Wengang, ZHOU Ling, DING Xiaoliang, XIE Cheng. Efficacy and safety of leflunomide for IgA nephropathy：A meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 60-67.

References

［1］Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis［J］. Kidney Int, 2012, Suppl(2): 139-274.
［2］张宏.KDIGO指南解读：IgA肾病治疗［J］.中国实用内科杂志，2012，32（12）：925-927.
［3］陈丁，吴杰，陈香美. IgA肾病的治疗现状及进展［J］.北京医学，2016，38（3）：257-260.
［4］Vecchio M, Bonerba B, Palmer SC, et al.Immunosuppressive agents for treating IgA nephropathy［J］. Cochrane Database Syst Rev, 2015,8: CD003965.
［5］赵先英，周小霞，张定林，等.来氟米特的临床应用进展［J］.国际检验医学杂志，2014，35（5）：591-593.
［6］邱晓楠，薛超，吴春香. 来氟米特与环磷酰胺治疗IgA肾病的Meta分析［J］. 临床和实验医学杂志，2014，13（7）：516-521.
［7］Liu Y, Xiao J, Shi X, et al.Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: A meta-analysis［J］. Exp Ther Med, 2016,11(1): 49-56.
［8］谢诚，丁肖梁，缪丽燕. 冠心病患者药物图层支架植入术后双抗血小板疗程的系统评价［J］. 中国药学杂志，2016，51（9）：762-768.
［9］王凉，孙铸兴. 来氟米特联合强的松治疗慢性进展性IgA肾病疗效分析［J］. 苏州大学学报(医学版)，2006，26（4）：677-679.
［10］傅鹏，于光，许静，等. 来氟米特联合激素延缓进展型IgA肾病肾功能减退的临床研究［J］.临床内科杂志，2006,23（11）:731-733.
［11］彭健韫，张小如，廖益飞，等. 来氟米特治疗慢性进展性IgA肾病的疗效观察［J］. 浙江实用医学，2009，14（2）：107-109.
［12］孙铸兴，王凉，刘斌，等. 来氟米特与环磷酰胺治疗伴肾功能减退IgA肾病的疗效对比分析［J］. 苏州大学学报（医学版），2009，29（5）：961-963.
［13］Liu XW, Li DM, Xu GS，et al. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome［J］. Int J Clin Pharmacol Ther, 2010,48(8): 509-513.
［14］张乐文.来氟米特联合激素治疗慢性进展性IgA肾病的疗效观察［J］.中国现代药物应用，2010，4（20）：116-118.
［15］张延. 来氟米特联合泼尼松治疗进展性IgA肾病的疗效［J］. 广州医学院学报，2010，38（4）：82-85.
［16］胡瑞海，刘东，贾微微，等. 来氟米特联合激素治疗IgA肾病临床观察［J］. 临床内科杂志，2011，28（12）：837-839.
［17］卜林，陈艳，孙东. 贝那普利联合来氟米特治疗IgA肾病的疗效［J］.江苏医药, 2012,38(11): 1277-1279.
［18］王秀玲，张岳光，张静. 来氟米特和强的松治疗IgA肾病的疗效及对IgA-纤维连接蛋白聚合物的影响［J］. 医药与保健，2014，22（1）：2-3.
［19］杨有芹，常晓东，程茂丽，等. 来氟米特联合糖皮质激素治疗进展性IgA肾病的疗效及对VCAM-1水平的影响［J］. 现代生物医学进展，2016，16（11）：2134-2137.
［20］田磊，邵兴华，谢园园，等. 免疫抑制治疗IgA肾病远期疗效的Meta分析［J］. 中华肾脏病杂志，2014，30（11）：833-840.

[1]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[2]	YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
[3]	YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang. Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
[4]	CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang. Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
[5]	LI Lujin, DING Junjie, LIU Dongyang, WANG Xipei, DENG Chenhui, JI Shangmin, CHEN Wenjun, MA Guangli, WANG Kun, SHENG Yucheng, XU Ling, PEI Qi, CHEN Yuancheng, CHEN Rui, SHI Jun, LI Gailing, WANG Yaning, WANG Yuzhu, XIE Haitang, ZHOU Tianyan, FANG Yi, ZHANG Jing, JIAO Zheng, HU Bei, ZHENG Qingshan. General considerations of model-based meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1250-1267.
[6]	SHAO Yaojun, ZHENG Tong,WANG Yanqiu,LIU Ling,YAO Yingshui. Nimodipine combined with flunarizine for preventing and treating migraine: A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 646-652.
[7]	WANG Weiyu, YU Hao. Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
[8]	WU Jiaqi, YANG Qiaowen, CHEN Xiumin, HUANG Runyue, HUANG Qingchun, ZHAO Yue, WU Xiaodong. Efficacy and safety of iguratimod combined with methotrexate in rheumatoid arthritis: A systematic review and Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1132-1140.
[9]	ZHOU Qiongxiu, ZHANG Jianna, YOU Xiaohan, LV Yinqiu, CHEN Bo, ZHANG Ji . Serum C4/C3 ratio in predicting the adverse prognosis of IgA nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 881-886.
[10]	ZHANG Xiaoyu, FANG Zhengmei, YAO Yingshui. Association of leptin and leptin receptor gene polymorphisms with hypertension: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 910-916.
[11]	LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen. Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.
[12]	RONG Guoyi, WANG Shumei, TANG Mo. Efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 787-794.
[13]	WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.
[14]	CHEN Jiaren, CUI Yudi, TIAN Hao, WANG Hao. Vortioxetine for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 52-59.
[15]	HU Jing, ZHU Jun-rong, YU Feng. Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303.